USFDA accepts Panacea Biotech's ANDA for breast cancer drug
Panacea Biotech confirms that the USFDA has accepted its abbreviated new drug application to evaluate its dossier for marketing paclitaxel protein-bound particles for injectable suspension in the US
Press Release / Media Release
Panacea Biotec Ltd. has delighted to announce that its abbreviated new drug application (ANDA) submitted under section 505(j) of the Federal Food, Drug and Cosmetic Act (FD&C; Act) for Paclitaxel Protein Bound Particles for injectable Suspension, 100mg/vial has been accepted for filing by the U.S. Food and Drug Administration (FDA). A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please. Updates
Panacea Biotec Limited has informed the Exchange regarding Corrigendum to Unaudited Financial Results (Provisional) for the quarter and half year ended 30th September, 2017' Press Release / Media Release
The Company is delighted to announce the signing of the agreement with Technology Development Board (TDB), Govt. of India for providing the financial assistance of Rs.28.99 Crores for the 'Development and commercialization of Dengue Tetravalent Vaccine (Live Attenuated, Recombinant, Lyophilized)'. A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please. I.Unaudited Financial Results (Provisional) For The Quarter And Half Year Ended 30Th September, 2017 Ii. Limited Review Report For The Quarter And Half Year Ended 30Th September, 2017
We would like to inform you that the Board of the Company has, at its meeting held on today, i.e. 14.11.2017, inter-alia, considered and approved the Unaudited Financial Results (Provisional) for the quarter and half year ended 30.09.2017. A copy of the Statement of Unaudited Financial Results (Provisional) for the quarter and half year ended 30.09.2017, approved by the Board of Directors pursuant to SEBI Listing Regulations, 2015 and... Standalone Financial Results, Limited Review Report for September 30, 2017
Panacea Biotec Ltd has informed BSE about : 1. Standalone Financial Results for the period ended September 30, 20172. Standalone Limited Review for the period ended September 30, 2017 Board Meeting On 14Th November, 2017 For Approving The Unaudited Financial Results (Provisional) For The Quarter And Half Year Ended 30Th September, 2017
This is to inform you that pursuant to Regulation 29 of the SEBI Listing Regulations, a Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 14th November, 2017 at New Delhi, inter-alia, to consider and approve the Unaudited Financial Results (Provisional) for the quarter and half year ended 30th September, 2017.... Newspaper Publication
Pursuant to Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Second Amendment Rules, 2017, the Company has published today i.e. 31st October, 2017, a notice for the attention of equity shareholders of the Company in respect of proposed transfer of equity shares of the Company to DEMAT Account of IEPF Authority in the Business Standard newspaper (All Editions) in English and Desh Sewak (Chandigarh Edition)... Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Panacea Biotec Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Declaration Of Postal Ballot Result Under Regulation 44(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Panacea Biotec Ltd. has declared the result of postal ballot today for raising of funds by way of issue of equity shares and/or other securities for an amount upto Rs.250 Crore and the above said resolution has been passed by the shareholders with the requisite majority.